AI-Enabled Healthcare Businesses as an Investment Thesis for 2026

By 2026, AI is no longer a differentiator in a pitch; it is an expectation. Nearly every healthcare and business-services company we meet has an AI story. That ubiquity is exactly why the bar for what we will actually back has gone up. When everyone has the technology, the technology stops being the thesis. What we underwrite instead is the business around it: the workflow it owns, the data it accumulates, the efficiency it can prove, and the compliance posture that lets it operate in a regulated market. This is how we are framing AI-enabled healthcare as an investment thesis going into 2026.

Durable Workflow Beats Clever Models

The most important question we ask is whether the company owns a workflow or merely improves one. A business that sits inside the daily process of getting paid, documenting care, scheduling patients, or managing authorizations, and that other systems and people now depend on, has something durable. A business that offers a smart feature riding on top of someone else's workflow has something that can be cloned, bundled away, or absorbed into the incumbent's roadmap.

Models are increasingly a commodity input. Capable underlying models can be rented by anyone, and the gap between vendors at the model layer is narrowing. Defensibility has migrated up the stack, to the workflow and the integrations that are expensive and slow to replicate. We would rather own a slightly less clever model embedded in an indispensable workflow than the cleverest model that lives outside the way work actually gets done.

The Data Moat Has to Be Real

Every company claims a data advantage; few have one. We distinguish between data that is merely large and data that compounds. A real moat exists when a company's data is proprietary, accumulates with usage, and feeds back into a product that gets measurably better as a result, creating a loop a competitor cannot shortcut by buying compute. Specialty-specific clinical data, payer-behavior data tied to denials, and operational data drawn from running a workflow at scale can all qualify, if they are genuinely hard for others to assemble.

What we discount is generic data that anyone could license, or volume without a feedback loop. The test is simple: would a well-funded competitor be able to reach the same data position quickly? If yes, it is not a moat. If the answer requires years of being embedded in customers' workflows, it might be.

Efficiency Has to Show Up in Numbers People Already Trust

We are pragmatic about AI because the market has trained us to be. The businesses worth backing deliver efficiency that lands in metrics the customer already tracks: days in accounts receivable, clean-claim rate, cost to collect, clinician hours returned, time to authorization, no-show rate. When value shows up in numbers the CFO and the medical director already watch, it is provable, and provable value sells itself and renews itself.

We are wary of efficiency claimed only in the vendor's own custom metrics, or in projections that depend on heroic adoption assumptions. The strongest signal of confidence is a willingness to price against outcomes, sharing in the value created rather than charging a flat platform fee and hoping the customer perceives the benefit.

Compliance Is a Feature, Not a Footnote

Healthcare is regulated, and that is a feature of the opportunity, not just a cost. Privacy, security, clinical governance, and the evolving rules around AI in clinical and administrative settings raise the barrier to entry and reward companies that take them seriously. We look for businesses that treat compliance and data governance as built-in, with the human-in-the-loop controls, auditability, and security posture that let a cautious health system or payer say yes. That maturity slows competitors and is a precondition for scaling inside large, risk-averse customers.

What We Will and Will Not Back

Putting it together, the businesses we find investable in 2026 share a profile: they own a durable workflow that customers depend on, they have a data position that compounds and is hard to copy, they prove efficiency in the customer's own trusted metrics, and they treat compliance as a competitive asset. They also tend to show the operating discipline we care about most, namely live production usage that persists, deep integration into systems of record, and a maintenance mindset that keeps the product current as rules and data drift.

What we pass on is the inverse: a thin AI feature on top of a borrowed workflow, a data story that is large but not compounding, efficiency that only exists in a slide, and a casual relationship with compliance. In a market where everyone has an AI story, that profile is increasingly common, and increasingly easy to mistake for a real business.

The Kiron Take

Our view going into 2026 is that AI has stopped being the thesis and become table stakes. The thesis is the business: durable workflow, a real data moat, provable efficiency, and compliance treated as an advantage. We partner with entrepreneurs who have built those fundamentals and added AI to make them stronger, not founders who hope AI will substitute for them. The technology will keep getting better and cheaper for everyone. The companies that endure will be the ones that turned it into something a customer cannot easily live without.